MediciNova (MNOV) News Today $1.66 -0.02 (-1.19%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period MediciNova (NASDAQ:MNOV) Shares Cross Above Two Hundred Day Moving Average - Should You Sell?MediciNova (NASDAQ:MNOV) Stock Crosses Above Two Hundred Day Moving Average - Time to Sell?October 30 at 2:26 AM | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comStockNews.com started coverage on MediciNova in a report on Wednesday. They set a "hold" rating on the stock.October 30 at 2:13 AM | marketbeat.comMediciNova announces update of Phase 2/3 MN-166 trial at NEALS meetingOctober 24, 2024 | markets.businessinsider.comMediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)October 23, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Research Coverage Started at StockNews.comStockNews.com began coverage on shares of MediciNova in a research note on Tuesday. They issued a "hold" rating on the stock.October 22, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.comStockNews.com began coverage on MediciNova in a research report on Monday. They set a "hold" rating on the stock.October 14, 2024 | marketbeat.comMediciNova (NASDAQ:MNOV) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comMediciNova (NASDAQ:MNOV) shareholders have endured a 73% loss from investing in the stock five years agoOctober 7, 2024 | finance.yahoo.comMNOV: MN-166 to be Evaluated in NIH-Sponsored Expanded Access Trial in ALS…September 30, 2024 | msn.comShort Interest in MediciNova, Inc. (NASDAQ:MNOV) Increases By 19.3%MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a significant increase in short interest during the month of September. As of September 15th, there was short interest totalling 224,600 shares, an increase of 19.3% from the August 31st total of 188,200 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 39,300 shares, the days-to-cover ratio is presently 5.7 days.September 30, 2024 | marketbeat.comMediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)September 30, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above Two Hundred Day Moving Average of $1.42MediciNova (NASDAQ:MNOV) Shares Pass Above 200 Day Moving Average of $1.42September 28, 2024 | marketbeat.comMediciNova, Inc. (NASDAQ:MNOV) Sees Large Increase in Short InterestMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) saw a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 188,200 shares, an increase of 104.3% from the August 15th total of 92,100 shares. Approximately 0.4% of the company's stock are sold short. Based on an average daily trading volume, of 40,500 shares, the days-to-cover ratio is presently 4.6 days.September 15, 2024 | marketbeat.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MNDSeptember 9, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above 200-Day Moving Average of $1.36MediciNova (NASDAQ:MNOV) Share Price Passes Above 200-Day Moving Average of $1.36September 4, 2024 | marketbeat.comMediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) MeetingSeptember 3, 2024 | globenewswire.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID ConditionAugust 29, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth PlansAugust 28, 2024 | finance.yahoo.comMNOV Sep 2024 2.500 call (MNOV240920C00002500)August 20, 2024 | finance.yahoo.comMediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.comStockNews.com began coverage on shares of MediciNova in a research report on Monday. They issued a "hold" rating on the stock.August 19, 2024 | marketbeat.comMediciNova, Inc. (MNOV)July 26, 2024 | finance.yahoo.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest UpdateMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the recipient of a significant decline in short interest in the month of June. As of June 15th, there was short interest totalling 110,700 shares, a decline of 18.4% from the May 31st total of 135,600 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 34,200 shares, the days-to-cover ratio is presently 3.2 days.June 29, 2024 | marketbeat.comMediciNova Chief Business Officer David H. Crean, Ph.D.June 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid CancerJune 5, 2024 | globenewswire.comMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024June 3, 2024 | globenewswire.comShort Interest in MediciNova, Inc. (NASDAQ:MNOV) Decreases By 25.5%MediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 158,600 shares, a decline of 25.5% from the April 30th total of 212,900 shares. Approximately 0.3% of the company's stock are short sold. Based on an average daily volume of 35,700 shares, the short-interest ratio is presently 4.4 days.May 30, 2024 | marketbeat.comMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic ConditionsMay 28, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 20, 2024 | stockhouse.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress SyndromeMay 14, 2024 | globenewswire.comMediciNova, Inc.: MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)May 7, 2024 | finanznachrichten.deMediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)May 7, 2024 | globenewswire.comMediciNova (NASDAQ:MNOV) investors are sitting on a loss of 89% if they invested five years agoApril 30, 2024 | finance.yahoo.comMediciNova, Inc. (NASDAQ:MNOV) Short Interest Down 26.0% in AprilMediciNova, Inc. (NASDAQ:MNOV - Get Free Report) was the target of a significant decrease in short interest during the month of April. As of April 15th, there was short interest totalling 247,000 shares, a decrease of 26.0% from the March 31st total of 333,600 shares. Based on an average daily volume of 49,400 shares, the days-to-cover ratio is presently 5.0 days. Currently, 0.5% of the shares of the company are sold short.April 27, 2024 | marketbeat.comMediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)April 2, 2024 | globenewswire.comMediciNova, Inc.: MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 27, 2024 | finanznachrichten.dePre-market Movers: IBIO, DRCT, NUVB, PAYS, LUXH…March 27, 2024 | msn.comMediciNova Gets Patent in Japan for Multiple Sclerosis-Related TreatmentMarch 27, 2024 | marketwatch.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 27, 2024 | tmcnet.comMediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in JapanMarch 26, 2024 | globenewswire.comMediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis SocietyMarch 20, 2024 | globenewswire.comCompanies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In GrowthMarch 20, 2024 | finance.yahoo.comMediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of ToxicologyMarch 12, 2024 | globenewswire.comMNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers…February 29, 2024 | finance.yahoo.comMedicinova IncFebruary 28, 2024 | money.usnews.comMediciNova, Inc.: MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaJanuary 17, 2024 | finanznachrichten.deMediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in ChinaJanuary 17, 2024 | finance.yahoo.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of ToxicologyDecember 21, 2023 | finance.yahoo.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeDecember 6, 2023 | markets.businessinsider.comMediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in EuropeDecember 6, 2023 | finance.yahoo.com Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here MNOV Media Mentions By Week MNOV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNOV News Sentiment▼0.370.43▲Average Medical News Sentiment MNOV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNOV Articles This Week▼21▲MNOV Articles Average Week Get MediciNova News Delivered to You Automatically Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies VRCA News Today KZR News Today HOOK News Today VYNE News Today NXTC News Today VSTM News Today ALDX News Today JSPR News Today LXEO News Today BTMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNOV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
